We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$3.24B 28.1%
34,230,523
+200
+0% +$20.9K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.45B 21.2%
45,725,556
– –
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.02B 8.87%
8,553,864
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.08B
$820M 7.11%
27,228,338
+1,408,570
+5% +$45M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12.9B
$676M 5.86%
7,583,084
+1,677,411
+28% +$146M
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$471M 4.09%
13,781,102
+622
+0% +$19.8K
ONC
7
BeOne Medicines Ltd
ONC
$42.4B
$376M 3.26%
3,849,231
-49,200
-1% -$4.5M
DBVT
8
DBV Technologies
DBVT
$914M
$136M 1.17%
550,956
– –
NGNE icon
9
Neurogene
NGNE
$773M
$129M 1.11%
546,708
– –
ASND icon
10
Ascendis Pharma A/S
ASND
$16.6B
$105M 0.91%
2,618,818
+269,978
+11% +$9.82M
ABLX
11
DELISTED
Ablynx NV
ABLX
$104M 0.9%
+4,161,118
New +$94M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$102M 0.88%
616,514
+211,029
+52% +$20.5M
AMRN
13
Amarin Corp
AMRN
$298M
$90.9M 0.79%
1,133,475
– –
AVXS
14
DELISTED
AveXis, Inc. Common Stock
AVXS
$85.8M 0.74%
775,000
– –
NBIX icon
15
Neurocrine Biosciences
NBIX
$15.5B
$77.9M 0.68%
1,004,624
+387,942
+63% +$26.5M
ARRY
16
DELISTED
Array Biopharma Inc
ARRY
$72.4M 0.63%
5,656,196
+442,668
+8% +$5.04M
ONCE
17
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$71.2M 0.62%
1,384,130
– –
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$2.44B
$68.7M 0.6%
13,997,172
– –
PHXM
19
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$68M 0.59%
+309,007
New +$73M
NVTA
20
DELISTED
Invitae Corporation
NVTA
$66.2M 0.57%
7,288,300
– –
ARGX icon
21
argenx
ARGX
$65B
$60.7M 0.53%
961,754
+861,754
+862% +$28.2M
RYTM icon
22
Rhythm Pharmaceuticals
RYTM
$7.57B
$59.5M 0.52%
+2,049,020
New +$54.2M
MDGL icon
23
Madrigal Pharmaceuticals
MDGL
$11.9B
$56.5M 0.49%
615,684
+557,922
+966% +$31.9M
HRTX icon
24
Heron Therapeutics
HRTX
$60.4M
$55.4M 0.48%
3,060,641
+272,649
+10% +$4.45M
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$46.5M 0.4%
2,549,461
+280,263
+12% +$4.35M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2017 Portfolio in Review

As of Q4 2017, Julian Baker held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Julian Baker's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Julian Baker's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Julian Baker fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Julian Baker's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Julian Baker opened 8 new positions and closed 5 in Q4 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.